Pharmaceuticals, Biotechnology and Life Sciences
New clinical data and abstracts on Roche’s Esbriet (pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF) are being presented at the European Respiratory Society (ERS) congress in Amsterdam.
Bayer CropScience inaugurated its new European Oilseed Processing Center in Monheim at a ceremony attended by industry representatives, authorities, agricultural stakeholders and customers.
Eli Lilly and Company and Incyte Corporation have announced positive top-line results of RA-BEGIN, the third Phase 3 study evaluating the safety and efficacy of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis (RA).
Allergan plc has updated its second-half 2015 continuing operations financial forecast. The forecast reflects adjustments for the upcoming expected discontinued operations
The National Institutes of Health (NIH) has awarded $46 million for research for the Human Placenta Project, an initiative to revolutionize understanding of the placenta.
The National Institutes of Health (NIH) has awarded nearly $144 million in new grants to develop new tools and measures that can be used to investigate more effectively environmental exposures from the womb through later years in a child’s life.
Eli Lilly has entered into a settlement agreement to resolve patent litigation with Sanofi regarding its insulin glargine product, Basaglar.
Phase II study of its Cyramza (ramucirumab) in combination with docetaxel met its primary endpoint, demonstrating a statistically significant increase in progression-free survival (PFS) for patients with locally advanced or metastatic urothelial carcinoma who failed prior platinum-based therapy.
Anavex Life Sciences Corp, a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS)…